Stocks Health care FENC
NASDAQ · Health careFennec Pharmaceuticals Inc. (FENC)
Fennec Pharmaceuticals Inc. brought in $59.2M of revenue over the twelve months to June 30, 2026, up 77.8% from a year earlier. It posted a net loss of $3.3M. At June 30, 2026 it held $41.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Fennec Pharmaceuticals Inc.
- Net worth
- Fennec Pharmaceuticals Inc. has a market value (market cap) of $379.4M at the latest share price, and shareholders' equity of $42.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $44.6M (-6.1% year on year), with a net loss of $9.7M. Over the 12 months to June 30, 2026: revenue $59.2M, net loss $3.3M.
- Cash flow
- In fiscal 2025 operations used $12.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Fennec Pharmaceuticals Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Fennec Pharmaceuticals Inc. does
Fennec Pharmaceuticals Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker FENC.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $44.6M | -$9.7M | -$0.34 | n/a |
| 2024 | $47.5M | -$436K | -$0.02 | n/a |
| 2023 | $23.8M | -$16M | -$0.60 | n/a |
| 2022 | $1.8M | -$23.7M | -$0.90 | n/a |
| 2021 | n/a | -$17.3M | -$0.67 | n/a |
| 2020 | $170K | -$18.1M | -$0.76 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where FENC ranks in Health care
Latest SEC filings
What Fennec Pharmaceuticals Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 19, 2026Passive stake changed SCHEDULE 13G/A
- September 17, 2026Other event 8-K
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 85% to $17.9M versus the same quarter last year; diluted EPS $0.05 versus -$0.11.
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- June 11, 2026
- June 10, 2026
- May 22, 2026Other event 8-K
- May 18, 2026
Insider trades
What the people running Fennec Pharmaceuticals Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $1.3M worth of shares in the last 90 days and bought none on the open market. Most of the selling (89%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 31, 2026 | Andrade RobertCHIEF FINANCIAL OFFICER | Received as pay | 1,703 | - |
| October 31, 2026 | Hackman Jeffrey S.Chief Executive Officer, Director | Received as pay | 1,159 | - |
| October 31, 2026 | Evans Terry LChief Commercial Officer | Received as pay | 168 | - |
| October 31, 2026 | Sayad Pierre SargisChief Medical Officer | Received as pay | 168 | - |
| October 31, 2026 | Cioffi Christiana MarieChief Strategy Officer | Received as pay | 156 | - |
| October 12, 2026 | Andrade RobertCHIEF FINANCIAL OFFICER | Received as pay | 3,846 | $21.3K |
| October 12, 2026 | Hackman Jeffrey S.Chief Executive Officer, Director | Received as pay | 2,224 | $12.3K |
| October 12, 2026 | Evans Terry LChief Commercial Officer | Received as pay | 2,326 | $12.9K |
Who owns FENC
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Rosalind Advisors, Inc.13G, passive with 3 related filers | 9.6% | August 13, 2026 |
| Kam Lawrence13G, passive with 2 related filers | 8.2% | February 17, 2026 |
| Orin Hirschman13G, passive with 1 related filers | 7.1% | October 19, 2026 |
| Solas Capital Management, LLC13G, passive with 1 related filers | 5.4% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 105 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Rosalind Advisors, Inc. | 3,188,001 | +279,800 |
| AIGH Capital Management LLC | 2,486,038 | +504,537 |
| Solas Capital Management, LLC | 1,889,366 | -592,832 |
| BlackRock, Inc. | 1,727,069 | +358,893 |
| AWM Investment Company, Inc. | 1,160,296 | +440,161 |
| Vanguard Capital Management LLC | 839,306 | -57,838 |
| Prospect Capital Advisors, LLC | 497,800 | new |
| State Street Corp | 426,004 | +66,949 |
| Geode Capital Management, LLC | 402,566 | +30,828 |
| Jane Street Group, LLC | 233,877 | new |
| Potomac Capital Management, Inc. | 224,400 | 0 |
| Morgan Stanley | 221,920 | +10,812 |
| Vanguard Portfolio Management LLC | 199,998 | +31,525 |
| Northern Trust Corp | 167,922 | +15,799 |
| Marshall Wace, Llp | 138,758 | new |
| Renaissance Technologies LLC | 134,200 | new |
| Nuveen, LLC | 131,482 | +70,534 |
| Trexquant Investment LP | 119,122 | +67,253 |
| CenterBook Partners LP | 118,582 | new |
| Lion Point Capital, LP | 112,434 | 0 |
Insiders
8 insiders reported holding 3,355,669 shares in total, about $36.3M at the last price.
| Holder | Shares |
|---|---|
| Southpoint Capital Advisors LP10% owner | 2,744,7412,744,741 held indirectly |
| Andrade RobertCHIEF FINANCIAL OFFICER | 248,558 |
| Raykov RostyFormer Director | 124,411 |
| Hackman Jeffrey S.Chief Executive Officer, Director | 70,844 |
| Rallis Chris ADirector | 63,077 |
| Evans Terry LChief Commercial Officer | 42,808 |
| Sayad Pierre SargisChief Medical Officer | 32,328 |
| Cioffi Christiana MarieChief Strategy Officer | 28,902 |
Questions about FENC
What does Fennec Pharmaceuticals Inc. do?
Fennec Pharmaceuticals Inc. is a company in the Health care sector, listed on NASDAQ as FENC. Its shares trade on NASDAQ under the ticker FENC.
What is Fennec Pharmaceuticals Inc.'s net worth?
Fennec Pharmaceuticals Inc. has a market value (market cap) of $379.4M at the latest share price, and shareholders' equity of $42.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Fennec Pharmaceuticals Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $3.3M on revenue of $59.2M.
How much revenue does Fennec Pharmaceuticals Inc. make?
Over the twelve months to June 30, 2026 Fennec Pharmaceuticals Inc. reported revenue of $59.2M. That is 77.8% more than a year earlier.
When did Fennec Pharmaceuticals Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from November 2, 2026.
When is Fennec Pharmaceuticals Inc.'s next earnings report?
Fennec Pharmaceuticals Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare FENC with
Follow FENC
Get an email when Fennec Pharmaceuticals Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Fennec Pharmaceuticals Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.